

Severe *Streptococcus pyogenes* Infections, United Kingdom, 2003–2004

Theresa L. Lamagni, MSc*; Shona Neal*; Catherine Keshishian, MSc*; Neelam Alhaddad, MSc*; Robert George, MD*; Georgia Duckworth*; Jaana Vuopio-Varkila†; and Androulla Efstratiou, PhD*

The Centers for Disease Control and Prevention is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

The Centers for Disease Control and Prevention designates this educational activity for a maximum of 1 *AMA PRA Category 1 Credits*. Physicians should only claim credit commensurate with the extent of their participation in the activity.

This activity for 1 contact hour is provided by the Centers for Disease Control and Prevention, which is accredited as a provider of continuing education in nursing by the American Nurses Credentialing Center's Commission on Accreditations.

The Centers for Disease Control and Prevention is a designated provider of continuing education contact hours (CECH) in health education by the National Commission for Health Education Credentialing, Inc. This program is a designated event for the CHES to receive 1 Category I contact hour in health education, CDC provider number GA0082.

CDC has been reviewed and approved as an Authorized Provider by the International Association for Continuing Education and Training (IACET), 8405 Greensboro Drive, Suite 800, McLean, VA 22102, USA. CDC has awarded 0.1 of CEUs to participants who successfully complete this program.

CDC, our planners, and our presenters wish to disclose they have no financial interests or other relationships with the manufacturers of commercial products, suppliers of commercial services, or commercial supporters with the exception of Dr. George, and he wishes to disclose that he has received honoraria as a speaker for GlaxoSmithKline and Wyeth Vaccines.

Presentations will not include any discussion of the unlabeled use of a product or a product under investigational use.

Origination Date: January 14, 2008

Expiration Date: January 14, 2011

*Health Protection Agency, London, United Kingdom; and †National Public Health Institute, Helsinki, Finland

Directions for obtaining CE credit:

Course Evaluation

Continuing education credit for this activity is available through the *CDC Training and Continuing Education Online* system only. Please follow the instructions provided below.

To complete online evaluation:

- Go to *CDC/ATSDR Training and Continuing Education Online* at <http://www.cdc.gov/tceonline>. If you have not registered as a participant, click on **New Participant** to create a user ID and password; otherwise click on **Participant Login** and login.
- Once logged on to the *CDC/ATSDR Training and Continuing Education Online* website, you will be on the **Participant Services** page. Click on **Search and Register**. Use either search method to locate the course and click on **View**.
- Click on the course. The course information page will come up. Scroll down to **Register Here**. Click on the type of CE credit that you would like to receive and then **Submit**. Three demographic questions will come up. Complete the questions and then **Submit**.
- If you have already completed the course you may choose to go right to the evaluation. Complete the evaluation and **Submit**. A record of your course completion and your CE certificate will be located in the **Transcript and Certificate** section of your record.

If you have any questions or problems contact:

CDC/ATSDR Training and Continuing Education Online

1-800-41TRAIN or 404-639-1292

Email at ce@cdc.gov

After this activity the reader will be able to:

- Describe the geographic distribution of cases of *Streptococcus pyogenes* infection.
- Describe demographic profile of patients with *S. pyogenes* infection.
- Describe seasonal patterns of *S. pyogenes* infection.
- Describe the clinical presentation of patients with *S. pyogenes* infection.
- List 4 risk factors for *S. pyogenes* infection.
- List 4 potential public health actions for minimizing the effects of *S. pyogenes* infection.

Severe *Streptococcus pyogenes* Infections, United Kingdom, 2003–2004

Theresa L. Lamagni,* Shona Neal,* Catherine Keshishian,* Neelam Alhaddad,* Robert George,* Georgia Duckworth,* Jaana Vuopio-Varkila,† and Androulla Efstratiou*

As part of a Europe-wide initiative to explore current epidemiologic patterns of severe disease caused by *Streptococcus pyogenes*, the United Kingdom undertook enhanced population-based surveillance during 2003–2004. A total of 3,775 confirmed cases of severe *S. pyogenes* infection were identified over 2 years, 3.33/100,000 population, substantially more than previously estimated. Skin/soft tissue infections were the most common manifestation (42%), followed by respiratory tract infections (17%). Injection drug use was identified as a risk factor for 20% of case-patients. One in 5 infected case-patients died within 7 days of diagnosis; the highest mortality rate was for cases of necrotizing fasciitis (34%). Nonsteroidal antiinflammatory drugs, alcoholism, young age, and infection with *emm*/M3 types were independently associated with increased risk for streptococcal toxic shock syndrome. Understanding the pattern of these diseases and predictors of poor patient outcome will help with identification and assessment of the potential effect of targeted interventions.

Diseases caused by the Lancefield group A streptococcus *Streptococcus pyogenes* are among the most varied in terms of clinical spectra and severity, ranging from the ubiquitous pharyngitis to rarer life-threatening manifestations such as necrotizing fasciitis. Interest in these diseases was renewed after the United States and several countries in Europe reported increasing numbers of cases of invasive *S. pyogenes* disease during and since the 1980s (1). These apparent changes triggered several rapid global initiatives, coordinated by a World Health Organization working group, including review of microbiologic diagnostic methods and commencement of enhanced surveillance in several countries during the mid-1990s (2).

*Health Protection Agency, London, United Kingdom; and †National Public Health Institute, Helsinki, Finland

In light of these changes, a cohesive network of 11 countries was formed in September 2002 to gain insight into the epidemiology of severe *S. pyogenes* disease across Europe. This network was funded by the European Union Fifth Framework Programme (3). To meet the Strep-EURO program objectives, the United Kingdom and other countries established population-based enhanced surveillance of severe *S. pyogenes* disease. Surveillance was undertaken to obtain accurate and comparable measures of overall and disease-specific incidence among participants and to compare demographic, risk factor, and clinical profiles of case-patients between countries, as well as microbiologic characteristics of *S. pyogenes* isolates collected.

Methods

In accordance with the program objectives, the Public Health Laboratory Service (now part of the Health Protection Agency) initiated enhanced surveillance of severe *S. pyogenes* disease from January 1, 2003, through December 31, 2004. Cases were defined according to the US definition (*S. pyogenes* isolated from a sterile site) (4). Also included were cases in which *S. pyogenes* was isolated from a nonsterile site in combination with probable streptococcal toxic shock syndrome (STSS) or another severe manifestation (pneumonia, necrotizing fasciitis, puerperal sepsis, meningitis, or septic arthritis). STSS was defined according to US specifications that differentiate between confirmed and probable cases on the basis of recovery of a sterile or nonsterile site isolate, respectively (4).

To maximize case ascertainment, cases were identified from 2 sources: isolate referrals to the national reference laboratory (Streptococcus and Diphtheria Reference Unit [SDRU]) and surveillance reports made to the Communicable Disease Surveillance Centre (CDSC) (5). SDRU pro-

vides reference microbiology services to the United Kingdom; CDSC surveillance covers England, Wales, Northern Ireland, the Channel Islands, and the Isle of Man. Cases identified from each source were reconciled with each other by using automated techniques to match records on the basis of personal identifiers (date of birth, sex, hospital number, National Health Service number, SOUNDEx-coded surname) and geographic location, followed by loose matching and manual checking to allow records to differ slightly on any given matching parameter. Referring laboratories were sent a study questionnaire to obtain further information on the demographic profile of the patient, disease manifestations, markers of clinical severity, outcome, and possible sources of infection (6). Ethnicity of patients was sought and classified according to census groupings for rate calculation. Where an isolate had not been received by SDRU, this isolate was also requested.

Group A streptococcal isolates referred to SDRU were characterized according to their M protein by using conventional serologic and *emm* gene typing (7,8). Antimicrobial drug-susceptibility testing was conducted by referral laboratories according to local standard operating procedures.

Responses to completed questionnaires were entered and stored in a custom-made Access (Microsoft, Redmond, WA, USA) database. All reports were checked to ensure they met the case definition. Repeat episodes were defined as those occurring in the same patient >30 days after the initial episode; reports received within 30 days were considered part of the same episode. Data were extracted for statistical analysis into STATA statistical software release 8.2 (Stata Corporation, College Station, TX, USA). Descriptive statistics were undertaken on confirmed cases with χ^2 and *t* tests used to test statistical significance of differences between subgroups. Incidence rates were calculated by using midyear resident population estimates for the respective years, age groups, sexes, and regional populations, with exact 95% confidence intervals (CIs) calculated according to the Poisson distribution. The 2001 census data were used as denominators for calculating rates according to ethnic group. All denominators were obtained from the Office for National Statistics. Stepwise unconditional logistic regression analysis was conducted to examine the independence of explanatory variables and development of STSS; the likelihood ratio test was used to evaluate significance of explanatory variables within each model.

All analyses were made on data from the United Kingdom, Channel Islands, and Isle of Man, except for estimated rates of infection, which were calculated for the areas with dual reporting (England, Wales, Northern Ireland, Channel Islands, and Isle of Man). The last 2 areas were omitted for age-, sex-, and ethnicity-specific rate calculations because of unavailability of these population denominators.

Results

Overview of Surveillance Results

From January 1, 2003, through December 31, 2004, a total of 3,821 cases of severe *S. pyogenes* disease meeting the case definition were reported from laboratories across the United Kingdom, Channel Islands, and Isle of Man. Of these cases, 21% were identified from isolate referrals only, without a corresponding surveillance report. Among the 3,821 reports were 46 repeat episodes, 5 of which were third episodes. Excluding repeat episodes, severe *S. pyogenes* disease was diagnosed for 3,775 patients in the United Kingdom, Channel Islands, and Isle of Man in 2003 and 2004.

S. pyogenes was isolated from a sterile site from 3,742 (99%) case-patients, primarily from blood culture (89%, 3,352). Thirty-three cases without sterile site isolates were included on the basis of ≥ 1 of the following clinical indicators: probable toxic shock syndrome (13 cases), necrotizing fasciitis (15), pneumonia (4), and puerperal sepsis (3).

Questionnaires were received for 2,647 (70%) of 3,775 case-patients. Information available for case-patients for whom questionnaires were or were not returned indicated their similarity in terms of age (median age 48 and 45 years, respectively), sex (54% male for both), and strain characteristics (*emm*/M type and erythromycin resistance), although a slightly higher proportion of case-patients for whom a questionnaire was returned had disease onset in December–April (53% vs. 48%; χ^2 6.37, degrees of freedom [df] 1, *p* = 0.012).

Geographic Distribution of Cases

In 2003 and 2004 combined, the overall rate of severe *S. pyogenes* infections was 3.33/100,000 population for England, Wales, Northern Ireland, Channel Islands, and Isle of Man. Variations were seen across these countries, with report rates higher in England (3,413 cases, 3.41/100,000) than Wales (153 cases, 2.60/100,000, rate ratio [RR] 1.32, 95% CI 1.12–1.55) or Northern Ireland (72 cases, 2.11/100,000, RR 1.62, 95% CI 1.28–2.04) but not significantly higher than rates in the Channel Islands and Isle of Man (10 cases, 1.98/100,000, RR 1.55, 95% CI 0.83–2.88). Substantial variations were also apparent between the English regions, with rates higher in Yorkshire and Humber (4.92/100,000) than in any other English region: East Midlands (3.25), East of England (2.98), London (2.75), North East (3.66), North West (3.70), South East (2.79), South West (3.92), and West Midlands (3.51). Report rates decreased in 2004 (1,718 cases, 3.12/100,000, RR 0.89, 95% CI 0.83–0.95) compared with 2003 (1,930 cases, 3.53/100,000); decreases in Yorkshire and Humber, and London accounted for 85% of this decrease.

Demographic Profile of Case-Patients

Severe *S. pyogenes* infection reports were highly concentrated in elderly persons (≥ 75 years of age, 10.67/100,000) and the young (< 1 years of age, 9.70/100,000) (Figure 1). Rates for male patients were 22% higher than for female patients (3.65/100,000 vs. 2.98/100,000, RR 1.22; 95% CI 1.14–1.30); more male case-patients were found across all age groups, in particular, young adults (15–44 years of age), for whom rates were 61% higher for male than female patients (3.44/100,000 vs. 2.14/100,000, RR 1.61, 95% CI 1.43–1.80). Of 1,822 case-patients whose ethnicity was recorded, 1,727 (95%) were white, 58 (3%) from the Indian subcontinent, and 21 (1%) black African or Caribbean. Rates of severe *S. pyogenes* disease observed were significantly higher for whites (3.29) than for those of Indian subcontinent (2.46/100,000, RR 1.34, 95% CI 1.02–1.74) or black African or Caribbean origin (1.84/100,000, RR 1.79, 95% CI 1.16–2.75).

Seasonal Patterns of Infection

Marked seasonal peaks of severe *S. pyogenes* infection were observed in both years. Cases gradually increased from the end of October and first peaked near the end of January (2nd week of 2003, 51 cases; 4th week of 2004, 60 cases) before peaking again (higher) toward the end of March (12th week of 2003, 62 cases; 14th week of 2004, 64 cases) (Figure 2).

Clinical Manifestations of Cases

Clinical information was reported on the study questionnaire for 2,611 (69%) severe cases of *S. pyogenes* infection (Table 1). Approximately one fifth of patients were bacteremic but had no defined focus for infection. Of the remainder, skin/soft tissue was the most common focus of infection (42%, 1,099). Cellulitis was the most common manifestation, diagnosed for 881 (34%) patients; necrotizing fasciitis was diagnosed for 136 (5%) patients. Necrotizing fasciitis was rarely reported for pediatric case-patients (< 16 years of age, 1%); most (64%, 87/136) cases occurred in persons 16–60 years of age. The respiratory tract was the next most commonly affected system; 434 (17%) patients showed clinical signs of upper or lower respiratory tract infection. Pneumonia was diagnosed for 309 (12%) case-patients.

Confirmed STSS developed in 196 (8%) patients who had a diagnosis of severe *S. pyogenes* infection (Table 2); 28% of these patients had necrotizing fasciitis. STSS developed in 40% (55/136) of patients with necrotizing fasciitis compared with 6% of other patients (χ^2 224.14, df 1, $p < 0.001$). Use of nonsteroidal antiinflammatory drugs was positively associated with development of STSS (22% vs. 8%, χ^2 13.71, df 1, $p < 0.001$).

Multivariable analysis of patient, clinical, and microbiologic factors associated with development of STSS identi-




Figure 1. Age- and sex-specific annual incidence of severe *Streptococcus pyogenes* infection in England, Wales, and Northern Ireland, 2003–2004. Error bars show 95% confidence intervals.

fied age to be a strong predictor for STSS; risk for STSS was 5-fold greater for persons 15–44 years of age (odds ratio [OR] 5.42, 95% CI 2.22–13.23, $p < 0.001$) than for the reference group (children < 15 years of age). Persons 45–64 years of age had a 5-fold increased risk for STSS (OR 5.20, 95% CI 2.12–12.74, $p < 0.001$). Patients > 65 years of age had no increased risk for STSS compared with the pediatric reference group. Regardless of age, patients with necrotizing fasciitis had a 7-fold increased risk for STSS (OR 6.87, 95% CI 4.25–11.09, $p < 0.001$).

Four risk factors (alcoholism, injection drug use, malignancy, and use of nonsteroidal antiinflammatory drugs) were independently associated with development of STSS. Patients who used nonsteroidal antiinflammatory drugs had a 3-fold increased risk for STSS (OR 3.00, 95% CI 1.30–6.93, $p = 0.01$). Alcoholism was associated with a 2-fold increased risk for STSS (OR 2.52, 95% CI 1.27–5.03, $p = 0.008$). Conversely, patients with malignancies had a much lower risk for STSS (OR 0.34, 95% CI 0.12–0.96, $p = 0.042$), as did injection drug users (OR 0.23, 95% CI 0.10–0.56, $p = 0.001$). Patients infected with an *emm*/M3 type, which was the only strain associated with STSS, had a 3-fold increased risk for STSS compared with patients infected with the reference group (*emm*/R28) (OR 3.20, 95% CI 1.35–7.58, $p = 0.008$).



Figure 2. Seasonal trends in reports of severe *Streptococcus pyogenes* infection in the United Kingdom, 2003–2004. Moving average (6 wk) is the average count for the previous 6 weeks.

Table 1. Clinical manifestations of severe *Streptococcus pyogenes* infection, United Kingdom, 2003–2004

Manifestation	All case-patients, no. (%) [*]	Children <16 y of age, no. (%)	Adults 16–60 y of age, no. (%)	Adults >60 y of age, no. (%)
Skin/soft tissue infection	1,099 (42)	85 (27)	479 (39)	531 (50)
Cellulitis	881 (34)	59 (19)	362 (30)	457 (43)
Necrotizing fasciitis	136 (5)	4 (1)	87 (7)	45 (4)
Abscess	134 (5)	6 (2)	112 (9)	16 (2)
Erysipelas	24 (1)	2 (1)	9 (1)	13 (1)
Bacteremia with no defined focus	558 (21)	77 (24)	228 (19)	252 (24)
Respiratory tract infection	434 (17)	66 (21)	187 (15)	181 (17)
Pneumonia	309 (12)	27 (8)	139 (11)	143 (13)
Other lower respiratory tract infection	62 (2)	6 (2)	26 (2)	30 (3)
Pharyngitis/tonsillitis	51 (2)	26 (8)	16 (1)	9 (1)
Ear infection	22 (1)	8 (3)	9 (1)	5 (<1)
Epiglottitis	17 (1)	2 (1)	10 (1)	5 (<1)
Sinusitis	6 (<1)	4 (1)	0	2 (<1)
Septic arthritis	220 (8)	40 (13)	114 (9)	66 (6)
Puerperal sepsis	58 (2)	0	58 (5)	0
Acute abdominal infection†	49 (2)	5 (2)	31 (3)	12 (1)
Cardiac infection‡	48 (2)	2 (1)	36 (3)	10 (1)
Meningitis	37 (1)	18 (6)	12 (1)	7 (1)
Total	2,611 (100)	318 (100)	1,225 (100)	1,064 (100)

^{*}Includes patients without age information.

†Includes 14 patients with peritonitis, 1 with appendicitis, and 1 with pancreatitis.

‡Includes 42 patients with endocarditis, 4 with pericarditis, 1 with myocarditis, 1 with myocarditis and pericarditis.

Overall, 413 (19%) patients for whom *S. pyogenes* infection was the main underlying or contributory cause of death died within 7 days of initial microbiologic diagnosis. Necrotizing fasciitis was the most severe clinical manifestation for patients, according to specified markers; patients with this condition were most likely to be admitted to an intensive care unit (ICU) (77%) or to die within 7 days of diagnosis (34%). However, ICU admission (20%) and surgical intervention (24%) were not uncommon among other patients. Case-fatality rates were also high for patients with pneumonia, 32% of whom died within 7 days. Of the 58 young women in whom puerperal sepsis developed, 2 died. Development of STSS was strongly linked to risk for death; 84 (45%) of 185 patients with STSS died from their infection compared with 329 (16%) of 2,007 without STSS.

Patient Risk Factors

Information on risk factors was available for 61% of case-patients with severe *S. pyogenes* infection. Of these, lesions or wounds to the skin were reported for 31% (719). Skin is the most likely portal of entry recorded overall, especially among persons >60 years of age, 40% of whom had skin lesions. Information on the nature of these lesions was available for 617 case-patients. The 2 most common types were traumatic lesions (188) and chronic wounds (161). Traumatic lesions were most common among young adults (16–60 years of age, 9%); chronic wounds were most common among elderly persons (14%). Less common types of wounds were recorded that included insect bites (21 cases, 0.9%) and animal-

associated traumatic wounds (cat scratches and dog and human bites, 8 cases, 0.3%).

Of young adults with severe *S. pyogenes* infections, 459 (40%) were injection drug users (20% of case-patients of all ages). Other conditions commonly reported that could have predisposed persons to infection included malignancies (161) and diabetes (158), each noted for 7% of cases overall and 11% and 13%, respectively, among elderly persons. Nine percent (204) of infections were associated with healthcare, mostly postsurgical infections (118). Among pediatric case-patients (<16 years of age), varicella was the next most common predisposing factor noted after skin lesions, reported for 41 (14%) children. Overall, 566 (25%) case-patients did not have any particular predisposition, or risk for severe *S. pyogenes* infection on the basis of the common factors outlined (Table 3) or any others considered pertinent by the reporting clinician. Among pediatric case-patients, this proportion increased to 46% (132).

Discussion

As part of a wider European initiative to improve our understanding of the epidemiology of severe *S. pyogenes* infections, the United Kingdom has amassed one of the largest collections of such cases recorded. The >3,700 cases diagnosed in 2003–2004 resulted in a rate of 3.33/100,000 population for England, Wales, Northern Ireland, the Channel Islands, and Isle of Man. This rate was similar to rates reported for other European countries and the United States in the early 2000s (1,9,10), although lower than some estimates from Canada (11–13). In the 2-year study period, the overall rate of severe *S. pyogenes* infections decreased from

Table 2. Clinical markers of severe *Streptococcus pyogenes* infection in the United Kingdom, 2003–2004*

Marker	All case-patients (n = 2,611), no. (%)	Bacteremia with no defined focus (n = 558), no. (%)	Pneumonia (n = 309), no. (%)	Cellulitis (n = 881), no. (%)	Septic arthritis (n = 220), no. (%)	Necrotizing fasciitis (n = 136), no. (%)	Puerperal sepsis (n = 58), no. (%)
Clinical severity (n = 2,611)							
Hypotensive shock	494 (19)	101 (18)	70 (23)	155 (18)	43 (20)	80 (59)	13 (22)
STSS (hypotension + ≥2 listed below)	196 (8)	28 (5)	27 (9)	63 (7)	18 (8)	55 (40)	3 (5)
Renal impairment	381 (15)	69 (12)	50 (16)	149 (17)	40 (18)	58 (43)	3 (5)
Respiratory distress	288 (11)	41 (7)	113 (37)	67 (8)	20 (9)	33 (24)	1 (2)
Erythematous rash	231 (9)	30 (5)	15 (5)	135 (15)	13 (6)	17 (13)	4 (7)
Soft-tissue necrosis	254 (10)	0	8 (3)	116 (13)	13 (6)	136 (100)	3 (5)
Liver abnormality	185 (7)	31 (6)	23 (7)	65 (7)	14 (6)	31 (23)	3 (5)
Disseminated intravascular coagulation	131 (5)	21 (4)	14 (5)	40 (5)	10 (5)	35 (26)	6 (10)
Admission to ICU (n = 2,292)	451 (20)	76 (16)	68 (24)	136 (17)	40 (21)	101 (77)	8 (16)
Surgical intervention (n = 1,885)	443 (24)	21 (6)	19 (8)	131 (20)	106 (63)	106 (87)	10 (24)
Death within 7 d (n = 2,192)	413 (19)	97 (22)	87 (32)	121 (16)	17 (9)	43 (34)	2 (4)

*STSS, streptococcal toxic shock syndrome; ICU, intensive care unit.

3.53/100,000 to 3.12/100,000. This overall decrease was largely caused by a substantial decrease in 2 regions, Yorkshire and Humber, and London. Use of multiple sources for case ascertainment was an improvement over previously used methods. Previous methods, which relied solely on voluntary laboratory reporting, would have yielded a rate of 2.65/100,000 during this period. As with any study dependent on participation of local reporters, this study may have missed additional diagnosed cases.

Rates of severe diseases associated with *S. pyogenes* were markedly higher in male patients than in female patients, an observation not consistently found in other countries (12,14) but commonly found among patients with bacteremic infections in the United Kingdom (15,16). We did not observe any increased rate of severe *S. pyogenes* infections in black patients of African or Caribbean origin, as was found in a large study in the United States (17). Estimated rates were lower for black patients than for Asian or white patients. Because our study relied on clinician and microbiologist reporting of ethnicity, the proportion of patients reported as white may have been overestimated as a result of assumptions made without confirmatory information.

Marked seasonal patterns in severe *S. pyogenes* disease were evident during the study period, with an initial peak in December–January, followed by a strong peak in March–April. Preliminary comparisons among Strep-EURO participants suggest similar patterns in other European countries (18). Why these diseases should peak in late winter and early spring is not known. Seasonal patterns of viral respiratory infections with respiratory syncytial virus and influenza virus, which could make patients vulnerable

to invasive *S. pyogenes* infections, may play a role in early- to mid-winter *S. pyogenes* peaks but would not explain the main spring peak seen in the United Kingdom (Health Protection Agency, unpub. data).

Clinical information provided for these case-patients highlights the severity of these infections; 19% died within 7 days of the initial culture-positive specimen being obtained. This finding is consistent with overall case-fatality estimates during enhanced surveillance in the United Kingdom in 1994–1997 (25%) and estimates reported in other countries (14,17,19,20). However, only 1 of these studies defined a time frame for estimates or included the role of infection in the patient's death, as our study did. Case-fatality rates were particularly high for case-patients with necrotizing fasciitis, who accounted for only 5% of all cases but 10% of all deaths. Completion of the questionnaire could also have been biased in favor of more severe or interesting cases.

Among case-patients identified in this study, 12% had pneumonia, a value substantially higher than that noted by enhanced surveillance in the United Kingdom in 1994–1997 (5%) (20). However, our finding was consistent with those in studies in other countries (11,13,17,19,21,22). The case-fatality rate in our study (32% within 7 days of initial diagnosis) was substantially higher than that expected with community-acquired pneumonia (23).

STSS developed in 8% of the case-patients identified in our study. These patients had poor survival rates; 45% died within a week of initial diagnosis. STSS was most likely to develop in young adults, which is consistent with findings of a US study that reported a lower median age for STSS patients (24). Infection with an *emm*/M3 strain was

Table 3. Potential predisposing factors for severe *Streptococcus pyogenes* infection, United Kingdom, 2003–2004

Factor	All case-patients, no (%) [*]	Children <16 y of age, no. (%)	Adults 16–60 y of age, no. (%)	Adults >60 y of age, no. (%)
Skin lesion/wound	719 (31)	63 (22)	298 (26)	358 (40)
Trauma	188 (8)	13 (5)	99 (9)	76 (9)
Chronic wound	161 (7)	0	39 (3)	122 (14)
Surgery	118 (5)	10 (4)	48 (4)	60 (7)
Injection drug use	459 (20)	0	459 (40)	0
Healthcare-associated infection	204 (9)	15 (5)	79 (7)	109 (12)
Malignancy	161 (7)	11 (4)	49 (4)	100 (11)
Diabetes	158 (7)	3 (1)	40 (4)	115 (13)
Alcoholism	88 (4)	0	67 (6)	21 (2)
Recent childbirth	86 (4)	0	86 (8)	0
Steroid use	77 (3)	3 (1)	35 (3)	39 (4)
Contact with person with <i>S. pyogenes</i> infection [†]	57 (4)	7 (4)	34 (5)	16 (2)
Nonsteroidal antiinflammatory drug use	49 (2)	3 (1)	18 (2)	28 (3)
Varicella	47 (2)	41 (14)	4 (<1)	2 (<1)
Cardiovascular disease	45 (2)	3 (1)	9 (1)	33 (4)
Upper respiratory tract infection	39 (2)	9 (3)	24 (2)	6 (1)
Renal impairment	31 (1)	2 (1)	19 (2)	10 (1)
Other reported risk factor [‡]	112 (5)	30 (11)	41 (4)	41 (5)
No risk factors reported	566 (25)	132 (46)	173 (15)	260 (29)
Total	2,305 (100)	284 (100)	1,135 (100)	884 (100)

^{*}Includes patients without age information.

[†]Information available for 1,586 patients.

[‡]Noted for <30 patients.

associated with an increased risk for STSS. This finding is consistent with previous (unadjusted) findings from the United States (17) but different from findings from Canada, which only identified *emm*/M9, a strain uncommon in the United Kingdom, as associated with STSS (13). Alcoholism was associated with increased risk for STSS; this association was also found in other studies (13,22). However, risk for STSS was 3-fold greater for patients who were reported to have used nonsteroidal antiinflammatory drugs, despite adjustment for whether patients had necrotizing fasciitis, which is strongly associated with STSS. Because no data were collected about time, dose, indications for use, or which agent was taken, a causal link between use of nonsteroidal antiinflammatory drugs and STSS cannot be inferred from our findings. A confounding factor, such as delay in receiving appropriate treatment, which we did not adjust for in our analysis, could explain this finding. Patients who took nonsteroidal antiinflammatory drugs may have had early signs, such as extreme pain, which indicated a more severe infection. Nonetheless, this remains an interesting and potentially important observation in a controversial area where evidence supporting either immunologic impairment or augmentation caused by nonsteroidal antiinflammatory drugs remains unresolved (25). Other novel associations with STSS were made; e.g., STSS was less likely to develop in injection drug users or patients with malignancies than in other patients. These findings point to immunocompetence as a necessary mediator for development of STSS.

Questionnaires concerning possible predisposing factors have highlighted skin lesions as the most commonly identified potential source of infection, which is similar to findings in other countries (18,22). However, given the occult nature of *S. pyogenes* infections, as indicated by the high proportion (21%) of cases with no identified focus, several of these cases may have originated from respiratory tract colonization. This colonization could lead to transient bacteremia, which in turn seeded local tissue sites, possibly in the presence of local trauma.

In contrast to preliminary findings from other Strep-EURO participants (18), a substantial proportion of case-patients were injection drug users (20% overall and 40% among young adults). Regional breakdowns of risk factors were not undertaken in our analyses. However, regional differences in report rates are in part explainable by injection drug use–related cases, with highest overall rates in the Yorkshire and Humber region. This region had been identified as having a particular problem of severe *S. pyogenes* disease in injection drug users (26). Patterns of isolate referrals to the national reference laboratory over the past decade suggest an increase in severe *S. pyogenes* infection in injection drug users (27). The reasons behind this change remain unclear and warrant further investigation.

Most severe *S. pyogenes* cases in our study occurred sporadically in the community; only 9% were associated with healthcare interventions. One fourth of all case-patients and nearly 1 in 6 young adults had no particular risk factors identified. These findings highlight the likely eco-

nomic effect of these infections and the challenges in developing any effective prevention measure.

Analysis of information collected in this study has yielded some unique insights into these infections and has begun to provide an evidence base for mounting public health initiatives in the United Kingdom (28). High and rapidly ensuing mortality rates among these patients emphasize the need for early recognition and rapid treatment. Maintaining a high index of suspicion, especially where there are signs of possible necrotizing fasciitis, could clearly be life-saving. Further analysis of *emm*/M type distribution, a key virulence factor inducing immunologic memory, will assist in assessment of the potential effect of vaccines currently under development. Changes in the epidemiology of severe *S. pyogenes* infections since the last period of enhanced surveillance in the mid-1990s underline the need for periodic monitoring to detect changes in disease manifestations, risk groups, and microbiologic characteristics to develop strategies for control and management of these infections.

Acknowledgments

We thank the microbiology laboratories in the United Kingdom for reporting cases and referring isolates; Asha Tanna, Michaela Emery, and Chenchal Dhami for expert processing of isolates at SDRU; and the Health Protection Agency Group A Streptococcal Working Group for drafting recommendations on management of community cases of invasive group A streptococcal disease.

The Strep-EURO project was funded by the European Union Fifth Framework Research Programme (QLK2.CT.2002.01398).

Ms Lamagni is an epidemiologist at the Centre for Infections, Health Protection Agency, London, United Kingdom. Her research interests include the epidemiology of streptococcal and fungal infections and mortality rates of infected persons.

References

- Lamagni TL, Efstratiou A, Vuopio-Varkila J, Jasir A, Schalén C. Strep-EURO. The epidemiology of severe *Streptococcus pyogenes* associated disease in Europe. *Euro Surveill*. 2005;10:179–84.
- World Health Organization. Programme on streptococcal diseases complex. Report of a consultation; 1998 Feb 16–19; Geneva. EMC/BAC/98.7. Geneva: The Organization; 1998.
- Schalén C. European surveillance of severe group A streptococcal disease. *Euro Surveill*. 2002;6 [cited 2007 Jun 4]. Available from <http://www.eurosurveillance.org/ew/2002/020829.asp>
- The Working Group on Severe Streptococcal Infections. Defining the group A streptococcal toxic shock syndrome. Rationale and consensus definition. *JAMA*. 1993;269:390–1.
- Public Health Laboratory Service. Enhanced surveillance of invasive group A streptococcal infections. *Commun Dis Rep CDR Wkly*. 2002; 12:news [cited 2007 Jun 4]. Available from <http://www.hpa.org.uk/cdr/archives/2002/cdr5102.pdf>
- Health Protection Agency. Strep-EURO – severe *Streptococcus pyogenes* disease network. 2007 [cited 2007 Sep 24]. Available from <http://www.hpa.org.uk/hpa/inter/strep-EURO.htm>
- Johnson DR, Kaplan EL, VanGheem A, Facklam RR, Beall B. Characterization of group A streptococci (*Streptococcus pyogenes*): correlation of M-protein and *emm*-gene type with T-protein agglutination pattern and serum opacity factor. *J Med Microbiol*. 2006;55:157–64.
- Saunders NA, Hallas G, Gaworzewska E, Metherell L, Efstratiou A, Hookey JV, et al. PCR-enzyme-linked immunosorbent assay and sequencing as an alternative to serology for M-antigen typing of *Streptococcus pyogenes*. *J Clin Microbiol*. 1997;35:2689–91.
- Centers for Disease Control and Prevention. Active bacterial core surveillance report. Emerging Infections Program Network, Group A Streptococcus, 2003. Atlanta: The Centers; 2004 [cited 2007 Jun 4]. Available from <http://www.cdc.gov/ncidod/dbmd/abcs/surveys/gas03.pdf>
- Centers for Disease Control and Prevention. Active bacterial core surveillance report. Emerging Infections Program Network, Group A Streptococcus, 2004. Atlanta: The Centers; 2005 [cited 2007 Jun 4]. Available from <http://www.cdc.gov/ncidod/dbmd/abcs/surveys/gas04.pdf>
- Tyrrell GJ, Lovgren M, Kress B, Grimsrud K. Invasive group A streptococcal disease in Alberta, Canada (2000 to 2002). *J Clin Microbiol*. 2005;43:1678–83.
- Laupland KB, Ross T, Church DL, Gregson DB. Population-based surveillance of invasive pyogenic streptococcal infection in a large Canadian region. *Clin Microbiol Infect*. 2006;12:224–30.
- Hollm-Delgado MG, Allard R, Pilon PA. Invasive group A streptococcal infections, clinical manifestations and their predictors, Montreal, 1995–2001. *Emerg Infect Dis*. 2005;11:77–82.
- Eriksson BK, Norgren M, McGregor K, Spratt BG, Normark BH. Group A streptococcal infections in Sweden: a comparative study of invasive and noninvasive infections and analysis of dominant T28 *emm*28 isolates. *Clin Infect Dis*. 2003;37:1189–93.
- Griffiths C, Lamagni TL, Crowcroft NS, Duckworth G, Rooney C. Trends in MRSA in England and Wales: analysis of morbidity and mortality data for 1993–2002. *Health Stat Q*. 2004; (Spring):15–22.
- Health Protection Agency. Bacteraemia. *Klebsiella*, *Enterobacter*, *Serratia*, and *Citrobacter* spp. Age and sex distribution by species. London: The Agency. 2006 [cited 2007 Jun 4]. Available from http://www.hpa.org.uk/infections/topics_az/kesc/AgeSex_dist.htm
- O'Brien KL, Beall B, Barrett NL, Cieslak PR, Reingold A, Farley MM, et al. Epidemiology of invasive group A streptococcus disease in the United States, 1995–1999. *Clin Infect Dis*. 2002;35:268–76.
- Lamagni T, Siljander T, Darenberg J, Luca B, Bouvet A, Creti R, et al. Risk factors for invasive group A streptococcal infections in Europe. In: Abstracts of the 17th European Congress of Clinical Microbiology and Infectious Diseases; 2007 Mar 31–Apr 3; Munich. Boston: Blackwell Publishing; 2007. Abstract O266.
- Ekelund K, Darenberg J, Norrby-Teglund A, Hoffmann S, Bang D, Skinhoj P, et al. Variations in *emm* type among group A streptococcal isolates causing invasive or noninvasive infections in a nationwide study. *J Clin Microbiol*. 2005;43:3101–9.
- George RC, Efstratiou A, Monnickendam MA, McEvoy MB, Hallas G, Johnson AP, et al. Invasive group A streptococcal infections in England and Wales. In: Abstracts of the Thirty-ninth Interscience Conference on Antimicrobial Agents and Chemotherapy; 1999 Sep 26–29; San Francisco. Washington: American Society for Microbiology Press; 1999.
- Svensson N, Öberg S, Henriques B, Holm S, Kallenius G, Romanus V, et al. Invasive group A streptococcal infections in Sweden in 1994 and 1995: epidemiology and clinical spectrum. *Scand J Infect Dis*. 2000;32:609–14.
- Ekelund K, Skinhoj P, Madsen J, Konradsen HB. Invasive group A, B, C and G streptococcal infections in Denmark 1999–2002: epidemiological and clinical aspects. *Clin Microbiol Infect*. 2005;11:569–76.

23. Marston BJ, Plouffe JF, File TM Jr, Hackman BA, Salstrom SJ, Lipman HB, et al. Incidence of community-acquired pneumonia requiring hospitalization. Results of a population-based active surveillance study in Ohio. The community-based pneumonia incidence study group. *Arch Intern Med.* 1997;157:1709–18.
24. Hoge CW, Schwartz B, Talkington DF, Breiman RF, MacNeill EM, Engler SJ. The changing epidemiology of invasive group A streptococcal infections and the emergence of streptococcal toxic shock-like syndrome. A retrospective population-based study. *JAMA.* 1993;269:384–9.
25. Zerr DM, Rubens CE. NSAIDs and necrotizing fasciitis. *Pediatr Infect Dis J.* 1999;18:724–5.
26. Engler KH, Perrett K. Group A streptococcal bacteraemia in Yorkshire and the Humber: evidence of another problematic infection among injecting drug users. *Commun Dis Public Health.* 2004;7:123–7.
27. Efstratiou A, Emery M, Lamagni TL, Tanna A, Warner M, George RC. Increasing incidence of group A streptococcal infections amongst injecting drug users in England and Wales. *J Med Microbiol.* 2003;52:525–6.
28. Health Protection Agency. Group A Streptococcus Working Group. Interim UK guidelines for management of close community contacts of invasive group A streptococcal disease. *Commun Dis Public Health.* 2004;7:354–61.

Address for correspondence: Theresa L. Lamagni, Healthcare-Associated Infection and Antimicrobial Resistance Department, Health Protection Agency Centre for Infections, 61 Colindale Ave, London NW9 5EQ, United Kingdom; email: theresa.lamagni@hpa.org.uk

EMERGING INFECTIOUS DISEASES®

EID
Online
www.cdc.gov/eid

March 2006

Search
past issues

EID
Online
www.cdc.gov/eid

